The vaccine candidate being developed by GSK, in close collaboration with Sanofi, is based on Sanofi's recombinant protein-based technology used to produce an influenza vaccine, as well as the effective pandemic adjuvant technology of GSK.
Active discussions on supply of the vaccine are ongoing with global organizations, the USA and the EU Commission, with France and Italy on the negotiation team.
The headquarters of GlaxoSmithKline PLC is pictured in London on July 29, 2013.
Governments across the globe are forging agreements with vaccine makers in hopes of securing enough doses to inoculate their populations against the novel coronavirus that causes COVID-19.
"The government's race to secure vaccine deals makes a mockery of its own rhetoric on equitable global access to Covid-19 vaccines".More news: Brendan Gleeson Plays Donald Trump In New Series — TRAILER
Sanofi and GSK, which 1st teamed up in April, have confirmed in a assertion that regulatory approval for their vaccine could be gained by the first fifty percent of 2021 if medical info was positive.
Business secretary Alok Sharma said it was important the United Kingdom secured early access to "a diverse range of promising vaccine candidates, like GSK and Sanofi, to increase our chances of finding one that works so we can protect the public and save lives".
"In the meantime, it is crucial that we safe early entry to a various selection of promising vaccine candidates, like GSK and Sanofi, to enhance our likelihood of finding a single that will work so we can protect the general public and help save life".
This is the fourth deal the Government has signed for potential coronavirus vaccines, worth a combined 250 million doses. The government also has an agreement with AstraZeneca for 100 million doses of the vaccine it is developing alongside Oxford University. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/2 study to start in September, followed by a Phase 3 study by the end of 2020.
The latest agreement comes as the government confirmed that nearly 72,000 people have volunteered to receive information about participating in future vaccine studies following the launch of the NHS COVID-19 vaccine research registry last week.More news: Crude oil falls as USA stimulus talks trough
"In the second quarter, with lockdown measures, we have seen an impact on people's willingness, or being able to access vaccines", Chief Executive Emma Walmsley said on a media call, adding there were early signs the attitude was changing.
"We thank the Uk Authorities for confirmation of purchasing intent, which supports the major expenditure we are already producing as a corporation to scale up enhancement and generation of this vaccine".
"While this is good news, we don't have to be optimistic", added Bingham.
"The UK should refrain from pursuing these advance purchase deals with pharmaceutical corporations for COVID-19 vaccines".More news: Why Osimhen signed for Napoli despite ‘racism fear’